Pasireotide
- Generic Name
- Pasireotide
- Brand Names
- Signifor
- Drug Type
- Small Molecule
- Chemical Formula
- C58H66N10O9
- CAS Number
- 396091-73-9
- Unique Ingredient Identifier
- 98H1T17066
- Background
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
- Indication
For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
- Associated Conditions
- Acromegaly, Cushing's Disease
- Associated Therapies
- -
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2018-04-25
- Target Recruit Count
- 6
- Registration Number
- NCT01313559
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Emory University
- Target Recruit Count
- 42
- Registration Number
- NCT01270321
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Milton S. Hershey Medical Center
- Registration Number
- NCT01234974
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
- Conditions
- Interventions
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 198
- Registration Number
- NCT01137682
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Swedish Neuroscience Institute 550 17th Avenue, Suite 500, Seattle, Washington, United States
Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Robert R. Henry, MD
- Target Recruit Count
- 45
- Registration Number
- NCT01128192
- Locations
- 🇺🇸
CMR Center for Metabolic Research VASDHS, San Diego, California, United States
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00698464
- Locations
- 🇩🇪
Novartis Investigative site, Berlin, Germany
🇿🇦Novartis Investigative Site, George, South Africa
🇧🇪Universite Catholique de Louvain, Brussels, Belgium
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
- Conditions
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT00690430
- Locations
- 🇺🇸
University of Arizona / Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, Arizona, United States
🇺🇸Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda, California, United States
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 358
- Registration Number
- NCT00600886
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
🇺🇸Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv., Baltimore, Maryland, United States
🇺🇸University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes, Ann Arbor, Michigan, United States
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT00446082
- Locations
- 🇳🇴
Novartis Investigative Site, Oslo, Norway
🇺🇸Cedars Sinai Medical Center SC - 4, Los Angeles, California, United States
🇺🇸Stanford University Medical Center Stanford Cancer Center (3), Stanford, California, United States
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT00434148
- Locations
- 🇹🇷
Novartis Investigative Site, Fatih / Istanbul, Turkey
🇺🇸Stanford University Medical Center Stanford Cancer Center (3), Stanford, California, United States
🇺🇸University Chicago Hospital Dept. of Univ of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.